More than 158,000 doses of bamlanivimab-etesevimab and casirivimab-imdevimab were used after deauthorization on Jan. 24, 2022
Duration of Infectiousness Examined in COVID-19 Cases
65 and 24 percent of 34 cases continued to shed infectious virus at five and seven days after symptom onset
Pathway Programs for Medical School Diversity Disrupted by Pandemic
Programs targeting elementary and middle school-aged children more likely to be canceled
School-Aged Children Can Self-Swab for COVID-19 Testing
Close agreement seen between self-collected nasal swabs and swabs collected by health care workers for SARS-CoV-2 testing results